title: Hormonal regulation of regucalcin mRNA expression in osteoblastic MC3T3-E1 cells.
abstract: The effect of various hormones on regucalcin mRNA expression in osteoblastic MC3T3-E1 cells in vitro was investigated. Cells with subconfluency were cultured for 24 or 48 h in a medium containing either vehicle or various hormones without fetal bovine serum. Regucalcin mRNA expression was significantly increased after culture with parathyroid hormone (synthetic human PTH; 10(-7) M), insulin-like growth factor-I (IGF-I; 10(-8) M), or 17beta-estradiol (10(-10) or 10(-9) M) for 48 h. Culture with 1,25-dihydroxyvitamin D3 (10(-7) M) for 48 h caused a significant decrease in regucalcin mRNA expression. Regucalcin mRNA expression was significantly decreased after culture with tumor necrosis factor-alpha (1 or 10 ng/ml of medium) for 24 or 48 h. The effect of PTH or IGF-I in increasing regucalcin mRNA expression was not seen in the presence of staurosporine (10(-8) M), an inhibitor of protein kinase C, or PD98059 (10(-7) M), an inhibitor of mitosis-activated protein kinase (MAP kinase), respectively, suggesting that regucalcin mRNA expression is enhanced through intracellular signaling factors. This study demonstrated that regucalcin mRNA expression in osteoblastic MC3T3-E1 cells is regulated by various hormones.
authors.affiliation: Laboratory of Endocrinology and Molecular Metabolism, Graduate School of Nutritional Sciences, University of Shizuoka, Shizuoka 422-8526, Japan. yamamasa1155@yahoo.co.jp
authors.forename: Masayoshi
authors.initials: M
authors.lastname: Yamaguchi
authors.forename: Yasuko
authors.initials: Y
authors.lastname: Otomo
authors.forename: Satoshi
authors.initials: S
authors.lastname: Uchiyama
authors.forename: Taeko
authors.initials: T
authors.lastname: Nakagawa
mesh_terms: D016475:3T3 Cells; D000818:Animals; D002117:Calcitriol / Q000494:pharmacology; D002135:Calcium-Binding Proteins / Q000235:genetics*; D002454:Cell Differentiation / Q000187:drug effects / Q000235:genetics; D004305:Dose-Response Relationship, Drug; D004958:Estradiol / Q000494:pharmacology; D005419:Flavonoids / Q000494:pharmacology; D006728:Hormones / Q000494:pharmacology*; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000494:pharmacology; D047908:Intracellular Signaling Peptides and Proteins / Q000235:genetics*; D051379:Mice; D010006:Osteoblasts / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D010281:Parathyroid Hormone / Q000494:pharmacology; D012333:RNA, Messenger / Q000235:genetics* / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction / Q000379:methods; D015398:Signal Transduction / Q000187:drug effects / Q000235:genetics; D019311:Staurosporine / Q000494:pharmacology; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology
chemical_list: D002135:Calcium-Binding Proteins; D005419:Flavonoids; D006728:Hormones; D047908:Intracellular Signaling Peptides and Proteins; C470125:PTH protein, human; D010281:Parathyroid Hormone; D012333:RNA, Messenger; C513324:Rgn protein, mouse; D014409:Tumor Necrosis Factor-alpha; D004958:Estradiol; D007334:Insulin-Like Growth Factor I; D002117:Calcitriol; D019311:Staurosporine; C093973:2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one